CD340
E902871
CD340 is an alternative name for the human epidermal growth factor receptor 2 (HER2), a cell surface receptor tyrosine kinase often overexpressed in certain aggressive breast and gastric cancers.
Statements (47)
| Predicate | Object |
|---|---|
| instanceOf |
cell surface receptor
ⓘ
protein ⓘ receptor tyrosine kinase ⓘ |
| activatesPathway |
JAK-STAT signaling pathway
NERFINISHED
ⓘ
MAPK/ERK signaling pathway ⓘ PI3K-AKT signaling pathway NERFINISHED ⓘ |
| alternativeNameOf |
ERBB2
NERFINISHED
ⓘ
HER2 NERFINISHED ⓘ human epidermal growth factor receptor 2 NERFINISHED ⓘ |
| associatedWith |
aggressive breast cancer
ⓘ
metastasis ⓘ poor prognosis in breast cancer ⓘ poor prognosis in gastric cancer ⓘ tumor cell proliferation ⓘ tumor cell survival ⓘ |
| encodes | ERBB2 gene NERFINISHED ⓘ |
| formsComplexWith |
EGFR (ERBB1)
NERFINISHED
ⓘ
ERBB3 NERFINISHED ⓘ ERBB4 NERFINISHED ⓘ |
| hasBiologicalProcess |
cell differentiation
ⓘ
cell proliferation ⓘ epithelial cell development ⓘ signal transduction ⓘ |
| hasCDDesignation | CD340 ⓘ |
| hasCellularComponent |
cell surface
ⓘ
plasma membrane ⓘ |
| hasDomain |
extracellular ligand-binding domain
ⓘ
intracellular tyrosine kinase domain ⓘ single-pass transmembrane domain ⓘ |
| hasMolecularFunction |
protein tyrosine kinase activity
ⓘ
transmembrane receptor activity ⓘ |
| locatedOnChromosome | human chromosome 17q12 ⓘ |
| memberOf |
EGFR/ErbB family of receptor tyrosine kinases
NERFINISHED
ⓘ
ErbB receptor family NERFINISHED ⓘ |
| organism | Homo sapiens NERFINISHED ⓘ |
| overexpressedIn |
HER2-positive breast cancer
ⓘ
HER2-positive gastric cancer ⓘ |
| targetOf |
ado-trastuzumab emtansine
ⓘ
fam-trastuzumab deruxtecan NERFINISHED ⓘ lapatinib NERFINISHED ⓘ margetuximab NERFINISHED ⓘ neratinib NERFINISHED ⓘ pertuzumab ⓘ trastuzumab NERFINISHED ⓘ tucatinib NERFINISHED ⓘ |
| usedAsBiomarkerFor |
HER2-positive breast cancer
ⓘ
HER2-positive gastric cancer ⓘ |
Referenced by (1)
Full triples — surface form annotated when it differs from this entity's canonical label.